154 related articles for article (PubMed ID: 17657218)
1. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia.
Dijoseph JF; Dougher MM; Armellino DC; Evans DY; Damle NK
Leukemia; 2007 Nov; 21(11):2240-5. PubMed ID: 17657218
[TBL] [Abstract][Full Text] [Related]
2. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK
Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
[TBL] [Abstract][Full Text] [Related]
3. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.
George B; Kantarjian H; Jabbour E; Jain N
Immunotherapy; 2016 Feb; 8(2):135-43. PubMed ID: 26780449
[TBL] [Abstract][Full Text] [Related]
4. Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy.
O'Donnell RT; Pearson D; McKnight HC; Ma YP; Tuscano JM
Cancer Immunol Immunother; 2009 Oct; 58(10):1715-22. PubMed ID: 19294384
[TBL] [Abstract][Full Text] [Related]
5. Inotuzumab Ozogamicin: First Pediatric Approval.
Dhillon S
Paediatr Drugs; 2024 May; ():. PubMed ID: 38780741
[TBL] [Abstract][Full Text] [Related]
6. The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity.
Abuhay M; Kato J; Tuscano E; Barisone GA; Sidhu RS; O'Donnell RT; Tuscano JM
Cancer Immunol Immunother; 2016 Oct; 65(10):1169-75. PubMed ID: 27506529
[TBL] [Abstract][Full Text] [Related]
7. CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults.
Lanza F; Maffini E; Rondoni M; Massari E; Faini AC; Malavasi F
Cancers (Basel); 2020 Jan; 12(2):. PubMed ID: 32012891
[TBL] [Abstract][Full Text] [Related]
8. Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies.
Zheng S; Gillespie E; Naqvi AS; Hayer KE; Ang Z; Torres-Diz M; Quesnel-Vallières M; Hottman DA; Bagashev A; Chukinas J; Schmidt C; Asnani M; Shraim R; Taylor DM; Rheingold SR; O'Brien MM; Singh N; Lynch KW; Ruella M; Barash Y; Tasian SK; Thomas-Tikhonenko A
Blood Cancer Discov; 2022 Mar; 3(2):103-115. PubMed ID: 35015683
[TBL] [Abstract][Full Text] [Related]
9. Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design.
Müller F; Cunningham T; Liu XF; Wayne AS; Pastan I
Clin Cancer Res; 2016 Oct; 22(19):4913-4922. PubMed ID: 27114443
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.
Mussai F; Campana D; Bhojwani D; Stetler-Stevenson M; Steinberg SM; Wayne AS; Pastan I
Br J Haematol; 2010 Aug; 150(3):352-8. PubMed ID: 20528877
[TBL] [Abstract][Full Text] [Related]
11. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Zhao Y; Short NJ; Kantarjian HM; Chang TC; Ghate PS; Qu C; Macaron W; Jain N; Thakral B; Phillips AH; Khoury J; Garcia-Manero G; Zhang W; Fan Y; Yang H; Garris RS; Nasr LF; Kriwacki RW; Roberts KG; Konopleva M; Jabbour EJ; Mullighan CG
medRxiv; 2023 Dec; ():. PubMed ID: 38106221
[TBL] [Abstract][Full Text] [Related]
12. CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia.
Jin X; Sun R; Li Z; Wang X; Xiong X; Lu W; Lyu H; Xiao X; Tian Y; Zhang H; Fang Z; Wang L; Zhao M
Haematologica; 2024 May; ():. PubMed ID: 38695137
[TBL] [Abstract][Full Text] [Related]
13. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
Advani A; Coiffier B; Czuczman MS; Dreyling M; Foran J; Gine E; Gisselbrecht C; Ketterer N; Nasta S; Rohatiner A; Schmidt-Wolf IG; Schuler M; Sierra J; Smith MR; Verhoef G; Winter JN; Boni J; Vandendries E; Shapiro M; Fayad L
J Clin Oncol; 2010 Apr; 28(12):2085-93. PubMed ID: 20308665
[TBL] [Abstract][Full Text] [Related]
14. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
Kantarjian H; Thomas D; Jorgensen J; Jabbour E; Kebriaei P; Rytting M; York S; Ravandi F; Kwari M; Faderl S; Rios MB; Cortes J; Fayad L; Tarnai R; Wang SA; Champlin R; Advani A; O'Brien S
Lancet Oncol; 2012 Apr; 13(4):403-11. PubMed ID: 22357140
[TBL] [Abstract][Full Text] [Related]
15. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.
de Vries JF; Zwaan CM; De Bie M; Voerman JS; den Boer ML; van Dongen JJ; van der Velden VH
Leukemia; 2012 Feb; 26(2):255-64. PubMed ID: 21869836
[TBL] [Abstract][Full Text] [Related]
16. Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP.
DiJoseph JF; Dougher MM; Evans DY; Zhou BB; Damle NK
Cancer Chemother Pharmacol; 2011 Apr; 67(4):741-9. PubMed ID: 20521053
[TBL] [Abstract][Full Text] [Related]
17. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.
Takeshita A; Yamakage N; Shinjo K; Ono T; Hirano I; Nakamura S; Shigeno K; Tobita T; Maekawa M; Kiyoi H; Naoe T; Ohnishi K; Sugimoto Y; Ohno R
Leukemia; 2009 Jul; 23(7):1329-36. PubMed ID: 19369961
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.
Jabbour E; O'Brien S; Huang X; Thomas D; Rytting M; Sasaki K; Cortes J; Garcia-Manero G; Kadia T; Ravandi F; Pierce S; Kantarjian H
Am J Hematol; 2015 Mar; 90(3):193-6. PubMed ID: 25407953
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.
Dornan D; Bennett F; Chen Y; Dennis M; Eaton D; Elkins K; French D; Go MA; Jack A; Junutula JR; Koeppen H; Lau J; McBride J; Rawstron A; Shi X; Yu N; Yu SF; Yue P; Zheng B; Ebens A; Polson AG
Blood; 2009 Sep; 114(13):2721-9. PubMed ID: 19633198
[TBL] [Abstract][Full Text] [Related]
20. Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53.
Tirrò E; Massimino M; Romano C; Pennisi MS; Stella S; Vitale SR; Fidilio A; Manzella L; Parrinello NL; Stagno F; Palumbo GA; La Cava P; Romano A; Di Raimondo F; Vigneri PG
Front Oncol; 2019; 9():57. PubMed ID: 30834235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]